Guggenheim analyst Yatin Suneja lowered the firm’s price target on Regeneron to $900 from $935 and keeps a Buy rating on the shares. The analyst continued pressure from a new competitor, Roche’s Vabysmo, is likely to temper Eylea’s recovery in Q2 from the seasonality impacts of Q1. The firm updated the model to reflect the increased Eylea headwinds but still sees COPD as a significant opportunity for Dupixent.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on REGN:
- Alnylam announces updated interim results from ALN-APP study
- Regeneron 483 issues might not require reinspection, says Morgan Stanley
- Regeneron gets FDA orphan drug designation for cemdisiran
- Regeneron to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2023
- REGN, CTLT Continue Sliding Following FDA Rejection of Eylea Drug